KBC Group NV Has $16.66 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

KBC Group NV cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 37.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,566 shares of the medical research company's stock after selling 50,319 shares during the period. KBC Group NV owned approximately 0.16% of Charles River Laboratories International worth $16,657,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Sumitomo Mitsui Trust Group Inc. boosted its stake in Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock worth $22,060,000 after purchasing an additional 3,714 shares during the period. Baillie Gifford & Co. lifted its stake in shares of Charles River Laboratories International by 1.6% in the third quarter. Baillie Gifford & Co. now owns 68,585 shares of the medical research company's stock valued at $13,509,000 after buying an additional 1,048 shares in the last quarter. Apollon Wealth Management LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter worth about $201,000. WCM Investment Management LLC grew its holdings in Charles River Laboratories International by 33.3% during the 3rd quarter. WCM Investment Management LLC now owns 10,367 shares of the medical research company's stock valued at $2,056,000 after buying an additional 2,589 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in shares of Charles River Laboratories International by 61.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 1,616 shares of the medical research company's stock valued at $318,000 after purchasing an additional 614 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

CRL has been the subject of a number of research analyst reports. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a research note on Friday, September 20th. Barclays dropped their price target on Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating for the company in a research report on Thursday, August 8th. Bank of America cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the company from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Evercore ISI boosted their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research note on Thursday, November 7th. Finally, UBS Group upped their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and an average target price of $217.54.

Charles River Laboratories International Price Performance

NYSE CRL traded down $9.16 during trading hours on Friday, hitting $187.74. 1,499,025 shares of the company's stock traded hands, compared to its average volume of 624,577. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The company has a market capitalization of $9.60 billion, a PE ratio of 23.50, a PEG ratio of 5.33 and a beta of 1.38. The firm's 50-day moving average is $195.26 and its 200-day moving average is $207.52. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International's quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.72 earnings per share. Equities analysts forecast that Charles River Laboratories International, Inc. will post 10.19 EPS for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's leadership believes its stock is undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).